home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

MorphoSys AG - American Depositary Shares (NQ:MOR)

18.96 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MorphoSys AG - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Dow Surges 100 Points; Cogent Biosciences Shares Plunge ↗

December 11, 2023

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.28% to 36,349.22 while the NASDAQ fell 0.36% to 14,352.34. The S&P...

Via Benzinga

Topics Stocks

Cigna Calls Off Humana Merger, Joins Macy's, Snap And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

December 11, 2023

U.S. stock futures were mixed this morning, with the Dow Jones futures trading almost flat on Monday.

Via Benzinga

Topics Stocks

MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

December 10, 2023

From MorphoSys AG

Via Business Wire

Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

December 07, 2023

U.S. stock futures traded mixed this morning, with the Dow Jones futures falling around 70 points on Thursday. Shares of Sprinklr, Inc. (NYSE: CXM) shares fell sharply in pre-market trading following...

Via Benzinga

Topics Stocks

Expert Ratings for MorphoSys ↗

November 22, 2023

Via Benzinga

Recap: MorphoSys Q3 Earnings ↗

November 15, 2023

Via Benzinga

Dell Reports Mixed Q3 Results, Joins Marvell Technology, Super Micro Computer And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

December 01, 2023

U.S. stock futures traded higher this morning, with the Dow Jones futures gaining more than 80 points on Friday.

Via Benzinga

Topics Stocks

La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday ↗

November 30, 2023

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 200 points on Thursday.

Via Benzinga

Topics Stocks

Zscaler Posts Q1 Results, Joins argenx, Cool Company And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 28, 2023

U.S. stock futures traded mixed this morning, with the Dow Jones futures gaining around 15 points on Tuesday.

Via Benzinga

Topics Stocks

MorphoSys's Earnings Outlook ↗

November 14, 2023

Via Benzinga

Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023

November 09, 2023

Via ACCESSWIRE

DLocal Posts Weak Results, Joins HP, Autodesk And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

November 22, 2023

U.S. stock futures traded higher this morning, with the Dow Jones futures gaining around 40 points on Wednesday.

Via Benzinga

Topics Stocks

Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

November 21, 2023

Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 21, 2023

Via Benzinga

Origin Materials Layoffs 2023: What to Know About the Latest ORGN Job Cuts ↗

November 21, 2023

Origin Materials layoffs have the company cutting 30% of its workforce as it plans to switch focus with a major restructuring.

Via InvestorPlace

Topics Workforce

Why Is Cancer Focused MorphoSys Stock Trading Lower Today? ↗

November 21, 2023

MorphoSys AG (NASDAQ: MOR) released topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib...

Via Benzinga

FSR Stock Alert: Fisker Receives Non-Compliance Notice From NYSE ↗

November 21, 2023

Fisker stock is falling on Tuesday as FSR investors react to a non-compliance notice and the resignation of its new CAO.

Via InvestorPlace

Why Is MorphoSys (MOR) Stock Down 20% Today? ↗

November 21, 2023

MorphoSys stock is falling on Tuesday with heavy trading of MOR shares despite the company posting positive data from a Phase 3 study.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 21, 2023

Via Benzinga

Why Symbotic Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket ↗

November 21, 2023

Shares of Symbotic Inc. (NASDAQ: SYM) surged in pre-market trading after the company reported better-than-expected fourth-quarter sales results.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

November 21, 2023

It's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!

Via InvestorPlace

AVITA Medical Cuts Revenue Forecast, Joins iQIYI, Trip.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 21, 2023

U.S. stock futures traded mostly lower this morning, with the Dow Jones futures falling around 50 points on Tuesday.

Via Benzinga

Topics Stocks

Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

November 20, 2023

Via ACCESSWIRE

MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

November 20, 2023

From MorphoSys AG

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 17, 2023

Via Benzinga

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

November 15, 2023

From MorphoSys AG

Via Business Wire

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

November 02, 2023

Via ACCESSWIRE

MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023

October 25, 2023

Via ACCESSWIRE

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023 ↗

October 13, 2023

Via Benzinga

Palo Alto Networks To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Friday ↗

October 13, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com